Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer

Clinical Chemistry

Volumn 63, Issue 3, 2017, Pages 691-699

  Riva, Francesca ^a,b   Bidard, Francois Clement ^a   Houy, Alexandre ^c   Saliou, Adrien ^a   Madic, Jordan ^a   Rampanou, Aurore ^a   Hego, Caroline ^a   Milder, Maud ^a   Cottu, Paul ^a   Sablin, Marie Paule ^a   Vincent Salomon, Anne ^a   Lantz, Olivier ^a,d   Stern, Marc Henri ^c   Proudhon, Charlotte ^a   Pierga, Jean Yves ^a,e  

^a INSTITUT CURIE   (France)

^b SAN GERARDO HOSPITAL   (Italy)

^c INSTITUT CURIE   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; NUCLEOTIDE; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA PROBE; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MITOSIS INDEX; NEOPLASM; OVERALL SURVIVAL; PLASMA; PROSPECTIVE STUDY; TISSUES; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; BLOOD; GENETICS; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

DNA, NEOPLASM; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85014476885     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.262337     Document Type: Article

References (21)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
2. Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. J Natl Cancer Inst 2015;107:djv015.
3. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34:1134-50.
4. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
5. Saliou A, Bidard FC, Lantz O, Stern M-H, Vincent-Salomon A, Proudhon C, et al. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. Expert Rev Mol Diagn 2016;16:39-50.
6. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci 2008; 1137:190-6.
7. Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013;5:207ps14.
8. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014;25:1729-35.
9. Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014;25:1959-65.
10. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015;9:783-90.
11. Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer 2015;136:2158-65.
12. Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res 2012;18:3934-41.
13. Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;369:93-4.
14. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
15. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 2015;7:313ra182.
16. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22.
17. Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem 2016;62:1129-39.
18. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302ra133.
19. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang M-HE, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015;7:1034-47.
20. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10.
21. Janni W, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 2016;22:2583-93.